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OBJECTIVES This study was designed to determine the incidence and prognostic significance of inducible
ventricular fibrillation (VF) in patients with coronary artery disease (CAD) and unexplained
syncope.
BACKGROUND Current American College of Cardiology/American Heart Association practice guidelines
recommend implantation of internal cardioverter-defibrillators (ICDs) in patients with
unexplained syncope in whom either ventricular tachycardia (VT) or VF is inducible during
electrophysiologic (EP) testing. Although the prognostic significance of inducible monomor-
phic VT is known, the significance of inducible VF remains undefined.
METHODS We evaluated 118 consecutive patients with CAD and unexplained syncope who underwent
EP testing. Sustained monomorphic VT was inducible in 53 (45%) patients; in 20 (17%)
patients, VF was the only inducible arrhythmia; and no sustained ventricular arrhythmia was
inducible in the remaining 45 (38%) patients. The latter two groups of 65 (55%) patients
make up the study population.
RESULTS There were 16 deaths among the study population during a follow-up period of 25.3 6 19.6
months. The overall one- and two-year survival in these patients was 89% and 81%,
respectively. No significant difference in survival was observed between patients with and
without inducible VF (80% power to detect a fourfold survival difference).
CONCLUSIONS In 17% of patients with CAD and unexplained syncope, VF is the only inducible ventricular
arrhythmia. Within the limits of this pilot study, long-term follow-up of patients with and
without inducible VF demonstrates no difference in survival between the two groups.
Therefore, the practice of ICD implantation in patients with CAD, unexplained syncope
and inducible VF, especially with triple ventricular extrastimuli, may merit reconsideration.
(J Am Coll Cardiol 2001;38:371– 6) © 2001 by the American College of Cardiology
Electrophysiologic (EP) testing is frequently performed to
identify an arrhythmic cause for unexplained syncope (1–
11). Because patients with syncope and inducible ventricular
tachycardia (VT) have an increased mortality (12,13), they
are often implanted with internal cardioverter-defibrillators
(ICDs), even in the absence of a clinically documented
sustained ventricular tachyarrhythmia (13–16). The ratio-
nale of this approach has been confirmed in follow-up
studies demonstrating, in these patients, a high incidence of
spontaneous VT requiring ICD therapy (13–16).
Although the adverse prognostic significance of inducible
monomorphic VT in these patients is clear, the significance
of inducible ventricular fibrillation (VF) is less certain
because induction of this arrhythmia during EP testing
(especially with triple ventricular extrastimuli) is generally
considered a nonspecific finding (17,18). Nonetheless, ac-
cording to current American College of Cardiology/
American Heart Association practice guidelines, induction
of “clinically relevant, hemodynamically significant sus-
tained VT or VF induced at electrophysiology study” in
patients with “syncope of undetermined origin” is a class I
indication for ICD implantation (19).
In this study, we evaluated patients with coronary artery
disease (CAD) and unexplained syncope who underwent
EP testing. All patients were treated with an EP-guided
approach, which included ICD implantation only in pa-
tients with inducible monomorphic VT. The specific aims
of this study were 1) to determine the incidence of inducible
VF in patients with CAD and unexplained syncope and 2)
to study the natural history of these patients.
METHODS
Study population. We evaluated 118 consecutive patients
with CAD and unexplained syncope who underwent EP
testing between January 1994 and December 1999. We
excluded patients with a documented sustained ventricular
arrhythmia or those resuscitated from sudden cardiac death.
Before undergoing EP testing, all patients underwent an
extensive evaluation, which failed to identify a cause for
syncope. This evaluation included at least 24 h of inpatient
or ambulatory ECG monitoring, assessment of left ventric-
ular ejection fraction (LVEF) by echocardiography, radio-
nuclide ventriculography or LV cineangiography and assess-
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ment of underlying CAD by stress testing with nuclear
perfusion imaging or cardiac catheterization. Patients with a
negative EP study were advised to undergo tilt testing,
which was performed according to one of our previously
published protocols (20,21).
EP testing. After written informed consent was obtained,
all patients underwent EP testing as previously described
(13). No patient was on an antiarrhythmic drug at the time
of clinical presentation or EP testing. Patients were locally
anesthetized with 0.25% bupivacaine and lightly sedated
with midazolam and/or morphine. Under fluoroscopic
guidance, two or three 5F or 6F quadripolar catheters with
5-mm interelectrode spacing (Bard EP, Billerica, Massa-
chusetts; Daig, Minnetonka, Minnesota) were advanced to
the high right atrium across the tricuspid valve to record a
His-bundle potential and to the right ventricular apex
and/or outflow tract. Bipolar intracardiac electrograms were
filtered at 30 to 500 Hz and displayed on a digital monitor.
Data were recorded on magnetic tape or optical disk (Prucka
Engineering, Houston, Texas). Programmed stimulation
was performed with an isolated current source (Bloom
Associates, Reading, Pennsylvania), and stimuli were deliv-
ered as rectangular pulses of 2 ms duration at four times
diastolic threshold with a minimum current of 2.0 mA.
Sinus node function was evaluated by the corrected sinus
node recovery time and sinoatrial conduction time. Atrio-
ventricular (AV) nodal function was assessed by atrial
extrastimulus testing and incremental atrial pacing. Pro-
grammed ventricular stimulation included up to triple ven-
tricular extrastimuli at two cycle lengths from two right
ventricular sites. Extrastimuli were delivered until ventricu-
lar refractoriness was reached. Patients with a negative
baseline study received isoproterenol (1–5 mg/min titrated
to increase heart rate by .20% over baseline), and pro-
grammed stimulation was repeated. No patient underwent
stimulation from the LV. Sustained monomorphic VT was
defined as the only positive end point of ventricular stimu-
lation.
Definitions. Coronary artery disease was defined as 1)
.50% reduction in luminal diameter of at least one of the
three major epicardial coronary arteries, 2) a documented
myocardial infarction (MI), or 3) a perfusion abnormality
on nuclear imaging in $1 coronary artery territory. Sinus
node dysfunction was defined as a corrected sinus node
recovery time $550 ms or a sinoatrial conduction time of
$125 ms. Significant His-Purkinje system dysfunction was
defined as: 1) an HV interval of $100 ms at baseline, or 2)
the development of infra-Hisian block with rapid atrial
pacing at a cycle length $400 ms. Sustained monomorphic
VT was defined as monomorphic VT, regardless of cycle
length, lasting $30 s or requiring termination because of
hemodynamic compromise. Patients with inducible VF
included those with sustained polymorphic VT as well as
VF. Deaths were classified as cardiac, noncardiac or un-
known, based on the assessment of the referring physicians.
Sudden death was defined as death occurring while the
patient was asleep or within 1 h of the onset of symptoms.
Therapy. Patients with inducible monomorphic VT (re-
gardless of cycle length of induced tachycardia) received a
tiered-therapy ICD. Noninducible patients with sinus node,
AV node, His-Purkinje system dysfunction or carotid sinus
hypersensitivity received a dual-chamber pacemaker. No
other patient, including those with inducible VF, received
antiarrhythmic drug or device therapy upon hospital dis-
charge.
Follow-up. Patients with an ICD or pacemaker were
followed in our arrhythmia clinic every three to six months.
Stored electrograms were retrieved from ICD recipients.
Patients who did not receive a device were followed by
telephone contact. Information was obtained from referring
physicians regarding initiation of new antiarrhythmic drugs,
recurrence of syncope or the identification of an alternative
etiology for syncope.
Statistical analysis. All continuous variables are expressed
as mean 6 SD. Comparisons of patients with inducible VF
and noninducible patients were made using the chi-square
or Fisher exact test (for categorical variables) and the
Student t test for independent samples (for continuous
variables). A Kaplan-Meier survival curve was generated to
compare the total mortality of patients with and without
inducible VF. Comparison of survival between the two
groups was made using the log-rank statistic. A p value
,0.05 was considered statistically significant.
RESULTS
Of the 118 patients with CAD and unexplained syncope
who underwent EP testing, 53 patients (45%) had inducible
monomorphic VT. These patients were reported previously
and were excluded from further analysis (13).
The remaining 65 patients (55%) (53 men, 12 women)
make up the study population. The mean age of these
patients was 69 6 10 years, and the mean LVEF was 42 6
13%. Twenty-seven patients (42%) had at least two syncopal
episodes before diagnostic evaluation. Triple-vessel CAD
was present in 36 patients (59%), and 34 patients (52%) had
a history of MI. Nonsustained VT (9 6 4 beats) was
documented in 27 (42%) patients. Demographics of the
study population are summarized in Table 1.
Abbreviations and Acronyms
AV 5 atrioventricular
CAD 5 coronary artery disease
EP 5 electrophysiologic
ICD 5 implantable cardioverter-defibrillator
LV 5 left ventricle, left ventricular
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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Noninvasive evaluation. The baseline rhythm was sinus in
57 patients (88%), atrial fibrillation or flutter in seven
patients (11%), and one patient (1%) was AV paced from a
permanent pacemaker previously implanted for 3° AV
block. Of the 57 patients in sinus rhythm, four patients (7%)
had first-degree AV delay. Bundle branch block was present
in 23 (35%) patients, which included left bundle branch
block in seven patients, right bundle branch block with a left
anterior or posterior hemiblock in 12 patients and a non-
specific intraventricular conduction delay in four patients.
Additional findings included pathologic Q waves in 15
patients (23%) and LV hypertrophy in three patients (5%).
Underlying CAD. Cardiac catheterization was performed
in 61 (94%) patients. Of these 61 patients, 11 (18%) had
single-vessel coronary disease, 14 (23%) had double-vessel
coronary disease, and 36 (59%) had triple-vessel coronary
disease. A diagnosis of CAD was made on the basis of
nuclear stress testing in the remaining four patients (6%).
Prior percutaneous transluminal coronary angioplasty had
been performed in 11 patients (17%), and 36 patients (55%)
had undergone prior coronary artery bypass grafting.
EP testing. Of the 57 patients with sinus rhythm in whom
sinus node function could be evaluated, sinus node dysfunc-
tion was documented in 16 (28%). An additional two
patients had carotid sinus hypersensitivity documented dur-
ing EP testing. Neither AV nodal re-entrant tachycardia
nor AV reciprocating tachycardia was inducible in any
patient. The mean HV interval was 53 6 10 ms. Only one
patient had severe His-Purkinje system dysfunction. In this
patient with underlying left bundle branch block, the HV
interval increased from 63 to 150 ms during rapid atrial
pacing.
Ventricular fibrillation was inducible in 20 (31%) of the
65 patients. These patients represent 17% of the 118
patients with CAD and unexplained syncope who under-
went EP testing. Induction was achieved with double
ventricular extrastimuli in two patients (10%) and with
triple ventricular extrastimuli in the remaining 18 patients
(90%) (Table 2). In one patient VF was induced only during
infusion of isoproterenol. The remaining 45 patients (69%)
had no inducible sustained ventricular arrhythmia. Patients
with and without inducible VF were similar with respect to
age, gender, LVEF, severity of CAD, underlying conduc-
tion system disease, ventricular effective refractory period
and length of follow-up (Table 1).
Therapy. Twenty-one (32%) of the 65 patients received a
permanent pacemaker. Indications for pacemaker implan-
tation included sinus node dysfunction in 13 patients, which
was documented during EP testing in 12 patients. In one
patient, despite normal sinus node function by EP param-
eters, an episode of symptomatic sinus bradycardia was
documented on telemetry the day after the EP study. Four
patients with documented sinus node dysfunction at EP
testing did not undergo pacemaker implantation. These
included three patients with minimal sinus node dysfunc-
tion (corrected sinus node recovery time of 579 ms and
sinoatrial conduction time of 131 and 135 ms, respectively)
and one patient (sinoatrial conduction time of 151 ms) who
refused pacemaker implantation.
Additional indications for pacemaker implantation in-
cluded AV node disease in two patients, manifest as atrial
fibrillation with a slow ventricular response; carotid sinus
hypersensitivity in two patients; His-Purkinje system dis-
ease in three patients and vasovagal syncope in one patient.
Table 1. Comparison of Inducible and Noninducible Patients
Inducible VF
(n 5 20)
Noninducible
(n 5 45)
Total
Population
(n 5 65) p Value
Age (yrs) 70 6 10 69 6 9 69 6 10 0.93
Gender (male) 17 (85%) 36 (80%) 53 (82%) 0.74
LV ejection fraction (%) 39 6 11 43 6 12 42 6 13 0.20
Episodes of syncope 0.28
1 10 (50%) 28 (63%) 38 (58%)
2 4 (20%) 11 (24%) 15 (23%)
$3 6 (30%) 6 (13%) 12 (19%)
Prior myocardial infarction 12 (60%) 22 (49%) 34 (52%) 0.44
Severity of coronary disease* 0.22
One-vessel 2 (10%) 9 (22%) 11 (18%)
Two-vessel 7 (35%) 7 (17%) 14 (23%)
Three-vessel 11 (55%) 25 (61%) 36 (59%)
History of nonsustained VT 9 (45%) 18 (40%) 27 (42%) 0.79
Bundle-branch block on ECG 8 (40%) 15 (45%) 23 (35%) 0.78
Baseline HV interval (ms) 51 6 10 54 6 10 53 6 10 0.31
Effective refractory period (ms)†
RVA 220 6 20 220 6 22 220 6 22 0.87
RVOT 221 6 19 222 6 23 222 6 22 0.75
Length of follow-up (days) 725 6 564 773 6 606 759 6 589 0.77
*Cardiac catheterization was not performed in four noninducible patients; †paced cycle length of 400 ms; p value 5 comparisons
between inducible and noninducible patients.
ECG 5 electrocardiogram; LV 5 left ventricular; RVA 5 right ventricular apex; RVOT 5 right ventricular outflow tract;
VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
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Patients with His-Purkinje system disease included two
patients with bifascicular block and recurrent syncope. The
patient with vasovagal syncope had a positive tilt test and
was treated with a beta-blocker. However, a pacemaker was
ultimately required because the patient developed intolera-
ble weakness and fatigue while on beta-blocker therapy.
The incidence of pacemaker implantation in patients with
inducible VF (four, 20%) was similar to patients without
inducible VF (17, 38%, p 5 0.16). No patient was dis-
charged on an antiarrhythmic drug or received an ICD.
Follow-up. Follow-up was available in 61 patients (94%) at
a mean of 25.3 6 19.6 days (range one to 72.1 months).
During this period, nine patients (15%) had at least one
recurrence of syncope. In two patients, neurocardiogenic
syncope was diagnosed on the basis of a positive tilt test,
which was not performed at the initial evaluation. In an
additional patient, syncope was attributed to hypotension
induced by overdiuresis. A cause for syncope could not be
determined in the other six patients. None of these nine
patients died during the follow-up period.
Sixteen patients (26%) died during the follow-up period
at a mean of 22.6 6 18.5 months (range 1.1 to 61.6
months). The one- and two-year survival in these patients
was 89% and 81%, respectively. Of these 16 patients, six had
inducible VF, and 10 were noninducible for any ventricular
tachyarrhythmia. There was no significant difference in the
overall survival of patients with and without inducible VF
(p 5 0.39, Fig. 1). We also compared the overall survival in
the subset of patients with an LVEF of #40%. In this
group, the survival of patients with inducible VF (n 5 10;
LVEF: 34 6 7%) was not different from patients without
inducible VF (n 5 24; LVEF: 33 6 8%, p 5 0.84).
Overall there were four cardiac deaths. Two deaths were
sudden (one in each group), one resulted from congestive
heart failure, and one resulted from an acute MI. There
were eight noncardiac deaths, with etiologies including
malignancy (n 5 2), respiratory failure (n 5 2), end-stage
renal disease (n 5 1), pancreatitis (n 5 1), sepsis (n 5 1)
Figure 1. Comparison of survival between patients with and without inducible ventricular fibrillation (VF). This Kaplan-Meier curve compares the overall
survival for patients with (dotted line 5 [VF(1)]) and without (solid line 5 [VF(2)]) inducible VF. There was no significant difference in survival between
the two groups. The numbers at the bottom represent the number of patients at risk.
Table 2. Patients With Inducible Ventricular Fibrillation
Patient Age EF (%) ERP (ms)
VF Coupling
Intervals
(ms)
1 72 35 220 400/250/180/190
2 83 45 210 500/220/170/180
3 78 35 N/A N/A
4 56 35 N/A N/A
5 76 45 220 400/240/200/150
6 78 35 210 400/250/190/170
7 75 40 220 600/260/210/180
8 77 25 250 600/270/180/180
9 56 45 210 400/210/170/180
10 77 55 190 400/200/160/140
11 64 50 200 400/240/200
12 62 50 210 400/230/160
13 76 55 200 400/210/150/140
14 56 20 250 400/260/190/160
15 58 40 180 400/200/140/130
16 81 40 200 400/230/150/150
17 70 35 240 600/260/220/200
18 61 20 220 400/210/140/140
19 81 50 250 600/280/190/180
20 54 20 240 400/230/170/170
EF 5 ejection fraction; ERP 5 effective refractory period (at site where VF was
induced); N/A 5 not available (VF induced with triple ventricular extrastimuli in both
patients); VF 5 ventricular fibrillation.
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and suicide (n 5 1). The causes of death were similar in
patients with and without inducible VF. In four patients (all
without inducible VF), the cause of death could not be
determined.
DISCUSSION
The principal finding of this study is that in 17% of patients
with CAD and unexplained syncope, VF is the only
inducible ventricular tachyarrhythmia. Ventricular fibrilla-
tion is most commonly induced with triple ventricular
extrastimuli. Long-term follow-up of patients with induc-
ible VF and those without an inducible ventricular tachy-
arrhythmia demonstrates no difference in survival, suggest-
ing that induction of VF with triple ventricular extrastimuli
in these patients may have no discernible prognostic signif-
icance.
In patients with CAD and unexplained syncope, the
induction of monomorphic VT appears to be a highly
specific finding. Long-term follow-up of these patients has
revealed a high incidence of spontaneous monomorphic VT
requiring ICD therapy (13–16). In fact, the cycle length of
the spontaneous VT is highly correlated with the cycle
length of VT induced during EP testing (16). It is impor-
tant to emphasize that, in contrast to some prior investiga-
tions (14,16), our definition of VF did not include patients
with an induced monomorphic tachycardia cycle length
#220 ms. We have previously demonstrated (13) that
induction of monomorphic VT is of prognostic significance,
regardless of the induced tachycardia cycle length.
Prior studies. The significance of inducible VF has been
evaluated in a number of prior studies. None of these studies
has demonstrated inducible VF to be of adverse prognostic
significance. In patients with recent MI, VF is inducible in
14% to 33% of patients; however, the one- and two-year
probability of remaining free from cardiac death or nonfatal
VT or VF is virtually identical to that of patients without
any inducible ventricular arrhythmia (22,23).
Findings in patients with syncope who undergo EP
testing suggest a similar conclusion. For example, in an
evaluation of 224 patients, including 137 patients who
presented with presyncope or syncope, VF was inducible in
8% of patients, most commonly with triple ventricular
extrastimuli (24). Patients with and without a history of
presyncope or syncope had a similar incidence of inducible
VF. No patient with inducible VF suffered a cardiac arrest
or sudden death during a follow-up period of more than two
years.
More recently, Link et al. (14) reported their experience
in 282 patients with unexplained syncope who underwent
EP testing. Their study population was heterogeneous with
respect to underlying cardiac diseases. Of these 282 patients,
82 had an inducible ventricular arrhythmia, including 16
patients with inducible VF. An ICD was implanted in nine
of these 16 patients; VF was induced with double ventricular
extrastimuli in six of these patients and with triple ventric-
ular extrastimuli in the remaining three patients. During
follow-up, although three of the six patients in whom VF
was induced with double ventricular extrastimuli had an
ICD discharge, none of the patients in whom VF was
induced with triple ventricular extrastimuli had an appro-
priate ICD discharge. However, because the ICDs were not
capable of providing stored electrograms, it was not possible
to determine the specific arrhythmia that precipitated the
ICD discharge.
Finally, Buxton et al. (25) recently reported follow-up of
patients with CAD, LVEF #40% and nonsustained VT
who underwent EP-guided therapy. Over a five-year
follow-up period, no difference in the arrhythmic event rate
was observed between patients who were noninducible and
those in whom polymorphic ventricular tachyarrhythmias
were induced with triple ventricular extrastimuli.
Study limitations. This study has several important limi-
tations. First, because all our patients had CAD, the
applicability of the data to other forms of structural heart
disease is unknown. In fact, several studies have suggested
that, in contrast to patients with CAD, patients with
nonischemic cardiomyopathy and unexplained syncope have
a poor prognosis even when no ventricular arrhythmia is
inducible during EP testing (26,27). Second, because VF
was rarely induced with double ventricular extrastimuli, our
study cannot determine whether there is a prognostic
difference between induction of VF with double or triple
ventricular extrastimuli.
Finally, this study is limited by its small sample size.
Therefore, it is possible that a “real” difference in survival
between patients with and without inducible VF may have
inadvertently been missed. For example, based on the
mortality data observed in these patients, our study had an
80% power to detect a fourfold difference in survival
between patients with and without VF. A more clinically
meaningful difference may be a 25% difference in survival
between patients with and without inducible VF. However,
to detect such a difference at a power of 80% (with an alpha
level of 0.05), a prospective study would need to enroll
approximately 2,500 patients. To date, the only study of this
magnitude performed in the field of electrophysiology was
MUSTT (25), which took nearly a decade to complete.
Therefore, in the foreseeable future, decisions regarding
management of patients with CAD, unexplained syncope
and inducible VF need to be made on the basis of observa-
tional data from smaller studies.
Clinical implications. Although the prognostic signifi-
cance of inducible monomorphic VT in patients with
unexplained syncope has been confirmed in several studies,
the significance of inducible VF has not been established.
Our data suggest that induction of VF in patients with
CAD and unexplained syncope may be of limited prognos-
tic significance. This finding is of significant clinical impor-
tance because VF is the only inducible ventricular arrhyth-
mia at EP testing (using up to triple ventricular extrastimuli)
in 17% of these patients. Therefore, the practice of ICD
375JACC Vol. 38, No. 2, 2001 Mittal et al.
August 2001:371–6 Significance of Inducible VF
implantation in patients with syncope of undetermined
origin in whom only sustained VF is induced during EP
testing, especially with triple ventricular extrastimuli, may
merit reconsideration.
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